# A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

> **NCT00808210** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Methotrexate
- **DRUG:** Methylprednisolone
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00808210
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-05
- **Primary completion:** 2012-11-14
- **Final completion:** 2012-11-14
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808210, "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00808210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*